Table 3.

Univariable analyses of biomarkers associated with overall survival and metastatic progression-free survival and exploratory subgroup analyses according to the treatment (n = 108).

Biomarker	Overall Survival
	All		ZA−		ZA+
	HR [95%CI]	p	HR [95%CI]	p	HR [95%CI]	p
CD8	1 [0.7; 1.6]	0.844	1.1 [0.7; 1.7]	0.61	0 [0; 4.6]	0.077
CD163	0.8 [0.7; 1]	0.011	0.8 [0.7; 1]	0.026	0.8 [0.7; 1.1]	0.184
CD68	0.9 [0.7; 1]	0.075	0.8 [0.7; 1]	0.054	1 [0.7; 1.3]	0.894
CSF-1R	1 [0.9; 1.2]	0.926	1 [0.8; 1.2]	0.96	1 [0.8; 1.3]	0.927
TRAP	1 [1; 1.1]	0.192	1.1 [1; 1.2]	0.017	1 [0.9; 1.1]	0.706
	Metastatic Progression Free Survival
	All		ZA−		ZA+
	HR [95%CI]	p	HR [95%CI]	p	HR [95%CI]	p
CD8	1.1 [0.7; 1.7]	0.807	1.2 [0.7; 1.9]	0.52	0.7 [0.2; 2.7]	0.609
CD163	0.9 [0.8; 1]	0.019	0.9 [0.7; 1]	0.081	0.8 [0.7; 1.1]	0.131
CD68	0.9 [0.8; 1]	0.147	0.9 [0.8; 1.1]	0.183	0.9 [0.7; 1.2]	0.557
CSF-1R	1 [0.9; 1.2]	0.514	1.1 [0.9; 1.3]	0.305	1 [0.8; 1.2]	0.887
TRAP	1 [1; 1.1]	0.214	1.1 [1; 1.1]	0.051	1 [0.9; 1.1]	0.888